Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | PAM | P19021 | 2/20 | 0.55 |
| ▸ | CES2 | O00748 | 3/20 | 0.54 |
| ▸ | CES1 | P23141 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.52 |
| ▸ | PPARG | P37231 | 6/20 | 0.52 |
| ▸ | PPARD | Q03181 | 6/20 | 0.52 |
| ▸ | PPARA | Q07869 | 6/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27778361 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL28126216 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL27771053 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL27640216 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL2734310 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL329071 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL3980640 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL8645409 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL4288902 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL28057936 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023118230-A2 | COMPOSITION COMPRISING A POLYHYDROXYALKANOATE COPOLYMER WITH A LONG HYDROCARBON-BASED CHAIN BEARING IONIC GROUP(S), AND METHOD FOR TREATING KERATIN MATERIALS USING THE COMPOSITION | L'OREAL (FR) | 2023-06-29 | — | — | WO | disclosed |
| US-11066351-B2 | Organic compound, three-dimensional organic framework formed by using organic compound, separation sieve and optical layer, which comprise organic framework, and optical device comprising optical layer as optical amplification layer | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) (KR) | 2021-07-20 | — | — | US | disclosed |
| EP-3810570-A1 | SOLID SUPPORT | Novartis AG (CH) | 2021-04-28 | — | — | EP | disclosed |
| EP-3655426-A1 | EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF | Novo Nordisk A/S (DK) | 2020-05-27 | — | — | EP | disclosed |
| EP-3612539-A1 | PHOSPHONIUM-ION TETHERED TETRACYCLINE DRUGS FOR TREATMENT OF CANCER | Rising Tide Foundation (CH) | 2020-02-26 | — | — | EP | disclosed |
| WO-2020036151-A1 | SEPARATING MATERIAL, METHOD OF MANUFACTURING SEPARATING MATERIAL, AND COLUMN | 日立化成株式会社 | 2020-02-20 | — | — | WO | disclosed |
| WO-2019234228-A1 | BETA-AMINO-ALPHA-HYDROXYALKYLPHENYL DERIVATIVES AND THEIR USE FOR CANCER TREATMENT | RISING TIDE FOUNDATION (CH) | 2019-12-12 | — | — | WO | disclosed |
| US-20190031586-A1 | ORGANIC COMPOUND, THREE-DIMENSIONAL ORGANIC FRAMEWORK FORMED BY USING ORGANIC COMPOUND, SEPARATION SIEVE AND OPTICAL LAYER, WHICH COMPRISE ORGANIC FRAMEWORK, AND OPTICAL DEVICE COMPRISING OPTICAL LAYER AS OPTICAL AMPLIFICATION LAYER | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2019-01-31 | — | — | US | disclosed |
| WO-2019016300-A1 | EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018193113-A1 | PHOSPHONIUM-ION TETHERED TETRACYCLINE DRUGS FOR TREATMENT OF CANCER | NOVINTUM BIOTECHNOLOGY GMBH (CH) | 2018-10-25 | — | — | WO | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999029640-A2 | COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF FIBROBLAST GROWTH FACTOR | EISAI CO., LTD. (JP) | 1999-06-17 | — | — | WO | disclosed |
| US-5840493-A | DIAGNOSIS OF LATE ONSET DIABETES BY DETECTION OF MUTATIONS IN ADENOSINE TRIPHOSPHATE SYNTHASE OR TRANSFER RNA (LYS) GENES IN A BIOLOGICAL SAMPLE; LABELLED NUCLEOTIDE SEQUENCES AS DETECTORS; ACCURACY | MITOKOR (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0858473-A1 | LIQUID CRYSTAL POLYMERS | THE SECRETARY OF STATE FOR DEFENCE (GB) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997016471-A1 | LIQUID CRYSTAL POLYMERS | THE SECRETARY OF STATE FOR DEFENCE (GB) | 1997-05-09 | — | — | WO | disclosed |
| EP-0746557-A4 | INTRACELLULAR SIGNALLING MEDIATORS | CELL THERAPEUTICS INC (US) | 1997-05-02 | — | — | EP | disclosed |
| EP-0746557-A1 | INTRACELLULAR SIGNALLING MEDIATORS | CELL THERAPEUTICS, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995022546-A1 | INTRACELLULAR SIGNALLING MEDIATORS | CELL THERAPEUTICS, INC. (US) | 1995-08-24 | — | — | WO | disclosed |
| EP-0015824-B1 | METAL DITHIOPHOSPHATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ADDITIVES FOR LUBRICATING OILS | OROGIL (FR) | 1982-02-17 | — | — | EP | disclosed |
| EP-0015824-A1 | Metal dithiophosphates, process for their preparation and their use as additives for lubricating oils | OROGIL (FR) | 1980-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066351-B2 | Organic compound, three-dimensional organic framework formed by using organic compound, separation sieve and optical layer, which comprise organic framework, and optical device comprising optical layer as optical amplification layer | OR10J3, POF1B, ORC3 | DGKA 2494/4885LMNA 2924/4885PAM 1097/4885 |
| US-20190031586-A1 | ORGANIC COMPOUND, THREE-DIMENSIONAL ORGANIC FRAMEWORK FORMED BY USING ORGANIC COMPOUND, SEPARATION SIEVE AND OPTICAL LAYER, WHICH COMPRISE ORGANIC FRAMEWORK, AND OPTICAL DEVICE COMPRISING OPTICAL LAYER AS OPTICAL AMPLIFICATION LAYER | OR10J3, POF1B, ORC3 | DGKA 2494/4885LMNA 2924/4885PAM 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.